Electronic data collection was used in this open study to survey the safety and efficacy of nifedipine when used in the treatment of 3972 patients with mild to moderate essential hypertension. The safety and efficacy results are presented and discussed as well as the advantages, disadvantages and reliability of electronic data collection. The validity of data collected electronically has not previously been tested, such data having been assumed to be reliable. The pattern of adverse events reported in this study is compared with the pattern of reports to the Committee on Safety of Medicine (CSM), to Bayer UK and in a large paper-based study of nifedipine, in order to test these assumptions. Reported adverse medical events pre-treatment, prior to entry to the study and noted at visit 1, were compared with reports during treatment in the study at visits 2 and 3. The expected incidence of flushing and headache was seen which diminished with continued treatment. Reductions were seen in dyspnoea and impotence. Ankle oedema was observed and was not reduced by time alone. After one month of treatment with nifedipine 20 mg tablets twice daily, 66.5% of patients had a sitting phase V diastolic blood pressure of90 mmHg or below and 79% of 95 mmHg or below.
Introduction
A generation after thalidomide there are still no clear guidelines for risk assessment of drugs in any country operating a licensing or regulatory scheme. Major catastrophes, as with practolol, have occurred in spite of elaborate regulatory machinery", A recent report from the Committee on Safety of Medicines has recommended that the number of patients in prelicence clinical trials should not be increased but that post-marketing surveillance may need to be undertaken for drugs destined for widespread prolonged use 2 • Large numbers of patients may be needed for such studies; for example, to detect an adverse drug reaction at an additional incidence of 1 in 1000 against a spontaneous background incidence of 1 in 1000 requires a minimum of 20 300 patients to be exposed to the drug, where a false positive (a) error of 0.05 and a false negative ({3) error of 0.05 were assumed.
Nifedipine 20 mg tablets were licensed in the UK for the treatment of hypertension in 1982. Nifedipine tablets do not have a formal slow release mechanism, but are made of film-coated, micronized compressed nifedipine. Solubility ofnifedipine is low in this form and thus the drug is more slowly available than in the liquid contents of nifedipine capsules. The aims of this study were to review the tolerability and efficacy of this drug, and to test the viability and reliability of electronic data collection in a large number of patients. It was thought possible that this method of collecting data might induce some distortion; it was therefore considered important to check against known experience before large surveillance studies of new drugs are performed in this manner.
Patients and methods
A total of 3972 patients were entered into the study by 1865 doctors in 486 participating practices. Patients suffering from essential hypertension were eligible for the study if they had a sitting diastolic blood pressure (phase V) of between 95 and 115 mmHg. They were newly diagnosed patients or those for whom a change of their present antihypertensive medication was indicated for lack of tolerability or efficacy. Of the 3972 patients studied, 2772 patients had not previously been treated for hypertension, 346 had been treated with diuretics, 513 with betablockers, 180 with diuretics and beta blockers in combination and 161 with other antihypertensives.
A full medical history was taken, general examination performed and informed consent obtained before admission to the study. Those patients meeting the entry criteria after two pre-entry blood pressure checks were treated with nifedipine 20 mg tablets twice daily. Patients were reviewed and blood pressure measured after four and eight weeks. At the first monthly review, those patients whose sitting diastolic blood pressure was greater than 90 mmHg (Phase V) had their dose of nifedipine increased to 40 mg twice daily. Compliance was assessed by returned tablet count.
All data were recorded by on-line transmission to a central computer. Any practitioner having a microcomputer and communications modem capable of entering a system such as Prestel was able to use the programme. The most widely used microcomputer was the Commodore 64. Data was transmitted through an independent data network to a McDonnell-Douglas Seqoia. A similar system is understood to have been used in a survey of captopril", but the validity of data collected by this method has not previously been tested. A 'training' programme was available to practitioners to enable them to become familiar with the system before entering 'live' data. Some participants spent a long time using this, whilst others did not use it at all. Different pass words were used for training and live programmes to safeguard the real data. The central computer was available for 24 hours a day, with almost no 'down time' during the study period. The approximate procedural times o141-0768f89f 050272-04f$02.00fO
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The Royal taken were: to 'log-on' to the system, 1 min; to enter new patient details, 5 min; and to enter follow-up visit details or withdraw a patient, 2 min. In some practices the data entry was performed by only one of the participating doctors. The tight control of the protocol by the programme ensured a measure of uniformity between doctors. The data entered by some randomly selected doctors was compared against each other and the study means as a check of consistency, but time did not permit between doctor comparisons for every participant. The computer programme validated the data to limit protocol violations and to ensure that entry errors were kept to a minimum. The programme also required an entry in each field so avoiding the problem of missing data. At entry, enquiry was made for adverse events associated with any treatment taken for hypertension prior to entry to the study. Adverse events relating to the treatment with nifedipine were sought at each further visit. Ten specific common adverse events related to antihypertensive drugs were recorded and additionally, a free format entry field was provided for unusual or unexpected events. Adverse events Table 1 .
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Results
Mean blood pressures and heart rates for all patients at each visit are shown in Table 2 . There were highly significant falls (P< =0.001) in systolic and diastolic blood pressures between visits 1 and 2, and 1 and 3, and between visits 2 and 3. There was a statistically significant fall (P< =0.001) in heart rate between visits 1 and 2. These changes are shown in Table 2 .
Three patients died during the course of the study. A male aged 59 years suffering from hypertension and angina noted increasing angina after entry to the study; he was withdrawn and treated appropriately but 10 days later had a fatal myocardial infarction. A male aged 63 years experienced a cerebrovascular accident from which he died in spite of good control of blood pressure. The third patient was a female aged 63 years who suffered from pancreatitis, angina pectoris, cardiomyopathy and hypertension; she did not comply with the protocol as she was also taking propranolol, isosorbide mononitrate and glyceryl trinitrate. The treating doctor, who in entering this patient ignored all the prompts relating to protocol violation given by the programme, did not think the death to be related to either nifedipine or the study.
Non fatal significant adverse events included one case of onychogryphosis, one case of postural hypotension, two cases of moderate left ventricular failure and one case of drowsiness and syncope.
A total of 561 patients withdrew because of adverse events; 161 patients were withdrawn from the study for violating the protocol, 33 patients were withdrawn for alternative treatment of their blood pressure, 39 patients did not comply with the treatment, and 36 patients elected to withdraw from the study.
Discussion
This study generated 11 megabytes of data (approximately equal to 90 editions of the JRSM 1 or 2, mild or moderate in nature. Fourteen per cent (561 of 3972) of patients were withdrawn from the study due to adverse events. Side effects due to nifedipine are thought to lessen with time and this trend was observed for all events except ankle swelling. As might be expected, considerable reductions in the reports of lethargy, dyspnoea, cold extremities and impotence were seen in the groups who had previously been taking beta-blockers or diuretics. The most commonly reported side effects of nifedipine treatment were skin flushing, headache and ankle swelling. The reduction in reports of dyspnoea in the previously untreated group (66 reduced to 23) might be due to the modest reduction of airways obstruction that has been observed with nifedipine". The number of reports of impotence was also reduced in the previously untreated group (15 reduced to 7), which probably reflects a true fall in the spontaneous rate for reasons which are unclear. Unusual adverse events will only appear in the free format entry fields so that these will always need to be searched manually, although 'word-search' facilities may be of some help.
The study was not blind and is therefore open to the criticism of bias. However, the large numbers of patients involved makes this less likely. Also, the specific adverse event inquiry produced an expected profile for flushing and headache suggesting that there had been little bias in recording. The Figure 1 . Specific reports expressed as a percentage ofthe total number of reports; this study and three other sources experience has shown that to collect this volume of information using paper records takes a considerable time and has the disadvantages of missing data, illegible entries and transcription errors. The electronic system collected data quickly and had many additional advantages such as date prompts for patient recall and aids for the prevention of unsafe practice. The data could quickly be searched for subgroups of patients, for example female overweight smokers, to see if they responded differently to the population as a whole. Testing the validity of the data is important if the method is to be used in the future in large studies similar to that with cimetidine", which must be considered the yardstick for good postmarketing surveillance.
Although there are considerable advantages in conducting a study in this way some problems were experienced which were peculiar to this method of data collection. The data was transmitted 'on-line' and 'line-breaks' were a constant source of frustration. The communication system monitored the amount of telephone line noise. This noise could interpose stray characters, and if this was likely to happen the system was automatically disconnected. Some practices in Northern Ireland had to withdraw because of the level of electronic interference experienced. Because of the problem of line breaks, future studies might utilize local storage of data on disk, transmitting the disk contents at intervals to the central computer. The text once entered was difficult to correct and participants overcame this in several original ways. For example, one investigator corrected her mistake by 'killing' the patient, thus increasing the death rate and demonstrating how electronics might distort the results.
Assessment of efficacy in this type of study is debatable", there being no control group and the study being open. However, the trend seen in this large group of patients is representative of what would happen in clinical practice to patients treated with this drug as monotherapy. A recent double blind study of nifedipine and atenolol singly and in combination", showed that either agent alone reduced the blood pressure of 60-70% of patients to below 95 mmHg, a similar fall to that seen in this study. Mean entry blood pressure in the nifedipine treated group in that study was 175.8/104.9, compared with 174.6/104.2 in this. The criterion which was set for control of sitting diastolic blood pressure of 90 mmHg or below after one month of treatment would now be considered to be too strict, however 66.5% (2217 of 3332) of patients achieved this control at visit 2. If the criterion for control of sitting diastolic blood pressure of 95 mmHg or below had been chosen for visit 2, it would have been achieved by 79% of patients. Heart rate was clinically unchanged between visits 1 and 2, when a rise might have been expected, especially as the population included patients who had been taking beta-blockers.
For assessment of tolerability and safety to be valid, the outcome for all patients should be known and one of the strengths of electronic data collection should be to identify non-attenders. Three hundred and twenty-two patients failed to attend follow-up, possibly reflecting the fact that hypertension is a symptomless condition. The fate of these patients is unknown. In the recent captopril study, some 8000 of the 13295 patients were unaccounted for at the end of the study period. The majority of adverse events were of grade proportionate pattern of the reported incidence ofthe 10 specific adverse events was compared with that obtained from three other sources; spontaneous reports to the Committee on Safety of Medicines (CSM),spontaneous reporting to Bayer UK and events reported spontaneously as well as by direct questioning in a previous paper-based study of nifedipine in 3242 hypertensive patients" (Figure. 1) .
There is no easy or readily available test for reliability of adverse event data. Nifedipine has not been the subject of 'Prescription Event Monitoring', the only system where numbers of patients using a drug are known. The number of prescriptions written can be measured but does not accurately reflect the number of patients using a drug. Under-reporting of adverse events by doctors is common. It was therefore decided to try to define a pattern of events by expressing the number of events in a specific category as a percentage of the total number of events, since that total number is the only denominator available for all four sources. The standard may be taken as the pattern of reports to the CSM, the greatest similarity seen was between this study and that pattern. Interestingly, there is little similarity between the patterns of reporting to the CSM and spontaneous reports to Bayer UK. The validity of this test is obviously open to debate, but no other test is available. It may, however, provide an indication that electronic data collection will gather reliable information and be useful in conducting the large post marketing surveillance studies likely to be necessary in the future.
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